Goodhealth Taps Undenatured Type II Collagen to Enter Joint Care Market

Summary

Goodhealth, a New Zealand dietary supplement brand founded in 1987 by botanist John Blanchard, is positioning itself as the country's national nutrition brand with a focus on natural health products. The company's products are stocked in 1,142 pharmacy stores across New Zealand and more than 10,000 pharmacies worldwide, reaching 59 countries and regions. It holds FernMark, Medsafe GMP and RMP certifications, with retail coverage spanning Unichem, Life Pharmacy, Chemist Warehouse and Countdown Pharmacy.

As of 2026, Goodhealth has exhibited at the China International Import Expo for seven consecutive years and is developing cross-border e-commerce and livestreaming. Its flagship Bone Collagen uses UC-II undenatured type II collagen. Research published in Communications Biology in 2024 found that oral undenatured type II collagen works through an 'oral immune tolerance' mechanism, reducing disease incidence to 50 percent in an experimental collagen-induced arthritis model and decreasing expression of pro-inflammatory factors such as IL-17 and IL-22 in joints.

It also protects against intestinal pathology, remodels the IL-17/IL-22 network and regulates intestinal fucosylation and microbiome composition, further confirming the importance of the 'gut-joint axis' in arthritis.

Commentary

Goodhealth, a locally rooted New Zealand nutrition brand, is entering the joint care market with UC-II undenatured type II collagen, reflecting a global shift in the dietary supplement market from basic vitamins to functional, science-backed products. New Zealand's health supplement industry is highly export-dependent, and China is a key growth market. According to New Zealand Trade and Enterprise, China is New Zealand's second-largest export destination for health supplements, with export value of about NZ$320 million in 2024.

Goodhealth is stocked in 1,142 New Zealand pharmacies and has participated in the China International Import Expo for seven consecutive years, demonstrating its long-term commitment to the Chinese market. For NZ small and medium-sized enterprises, this case suggests that in China's highly competitive market, differentiated ingredients and scientific evidence are key to breaking through homogenisation. Compared with traditional hydrolysed collagen, undenatured type II collagen works through an oral immune tolerance mechanism and can reduce arthritis incidence — a selling point that aligns with the needs of China's ageing population and active sports participants.

However, it should be noted that China's market regulation is tightening, health food registration and filing cycles are long, and cross-border e-commerce channels, while convenient, face policy volatility risks. At the same time, Australasian brands in the Chinese market face intense competition from domestic brands such as By-Health and Swisse (which has been acquired by Chinese capital). Goodhealth reaches consumers through new formats such as cross-border livestreaming, offering SMEs a light-asset model worth emulating.

Yet reliance on a single core ingredient may expose it to raw material supply and patent risks. Its subsequent product line expansion and localisation strategy warrant attention.

Keywords: Goodhealth, undenatured type II collagen, joint health, New Zealand pharmacies, China International Import Expo, cross-border e-commerce, UC-II, oral immune tolerance, dietary supplements

Summary in Chinese | 摘要

源自新西兰的膳食营养补充剂品牌Goodhealth好健康，1987年由新西兰植物学专家约翰·布兰查德创立，至今已有39年品牌历史，定位为新西兰国民营养品牌，主营天然保健品、膳食补充剂的研发、生产与销售。目前该品牌已入驻新西兰1142家药房门店，全球超10000家药房在售，产品覆盖59个国家和地区，并持有新西兰银蕨认证、新西兰Medsafe颁发的GMP认证、RMP认证，完成新西兰主流药房的全渠道覆盖，Unichem、Life Pharmacy两大全国连锁药房以及Chemist Warehouse、Countdown Pharmacy等共同构成其零售网络。截至2026年，Goodhealth好健康公司已连续参展7届中国国际进口博览会，并积极发展跨境电商及跨境直播新业态。

其核心产品经典款骨胶原采用UC-II非变性II型胶原蛋白原料，据《Communications Biology》2024年发表的研究，口服非变性II型胶原蛋白可通过“口服免疫耐受”机制发挥作用，在实验性胶原诱导性关节炎模型中使疾病发生率降低至50%，并减少关节中IL-17和IL-22等促炎因子的表达，同时保护肠道病理、重塑IL-17/IL-22网络，调节肠道岩藻糖基化和微生物组组成，进一步印证了“肠-关节轴”在关节炎中的重要性。

Commentary in Chinese | 评论

Goodhealth作为新西兰本土营养品牌，其以UC-II非变性II型胶原蛋白切入关节养护赛道，反映了全球膳食补充剂市场从基础维生素向功能性、科学背书产品升级的趋势。新西兰保健品行业高度依赖出口，中国是其关键增长市场。据新西兰贸易发展局数据，中国是新西兰保健品第二大出口目的地，2024年出口额约3.2亿纽币。

Goodhealth已入驻新西兰1142家药房，并连续7年参加进博会，显示其对中国市场的长期投入。对NZ中小企业而言，该案例提示：在竞争激烈的中国市场，差异化原料和科学证据是突破同质化的关键。非变性II型胶原蛋白相比传统水解胶原蛋白，具有口服免疫耐受机制，能降低关节炎发生率，这一卖点契合中国老龄化与运动人群需求。

但需注意，中国市场监管趋严，保健食品注册备案周期长，跨境电商渠道虽便捷但面临政策波动风险。同时，澳新品牌在中国市场面临本土品牌如汤臣倍健、Swisse（已被中国资本收购）的激烈竞争。Goodhealth通过跨境直播等新业态触达消费者，为中小企业提供了可借鉴的轻资产模式。

然而，依赖单一核心成分可能面临原料供应和专利风险，建议关注其后续产品线扩展及本地化策略。

关键词: Goodhealth好健康, 非变性II型胶原蛋白, 关节健康, 新西兰药房, 中国国际进口博览会, 跨境电商, UC-II, 口服免疫耐受, 膳食营养补充剂

Source: The Beijing News Online